After a six-month pandemic-related delay, TransMedics (NSDQ:TMDX) is set to have an FDA panel review the premarket approval application for its donor heart transport technology on October 7, 2020. TransMedics’ organ care system (OCS) technology is designed to keep donated hearts, lungs and livers in near-living condition until transplantation. The FDA approved the Andover, Mass.-based company’s […]
J&J to acquire Momenta for $6.5B
Johnson & Johnson (NYSE:JNJ) announced today that it entered into an agreement to purchase Momenta Pharmaceuticals (NSDQ:MNTA) for $6.5 billion. New Brunswick, N.J.-based Johnson & Johnson will pay $6.5 billion in an all-cash transaction for the developer of novel therapies for immune-mediated diseases, according to a news release. Get the full story at our sister site, […]
BD names IR director
Becton Dickinson (NYSE:BDX) announced yesterday that it appointed Kristen Stewart as its new senior VP of strategy and investor relations. In the newly created position, Stewart is slated to work closely with the BD executive team to “drive shareholder value and communicate the company’s long-term growth strategy,” according to a news release. Stewart previously held roles […]
Alcon slides on missed Q2 earnings
Alcon (NYSE:ALC) shares dipped before hours today on second-quarter results that missed the consensus earnings forecast. The Geneva, Switzerland-based company posted losses of -$422 million, or -86¢ per share, on sales of $1.2 billion for the three months ended June 30, 2020, for an 8.2% bottom-line slide on a sales decline of -36.2%. Adjusted to exclude […]
Medtech stocks help boost S&P rally
Medtech stocks helped the S&P 500 Index reach record highs today amid a bounceback from the lows of the COVID-19 pandemic. Reuters reported that medtech played its part in the record turn of the market, with Abiomed (NSDQ:ABMD), Regeneron Pharmaceuticals (NSDQ:REGN) and West Pharmaceutical Services (NYSE:WST), all of which are involved in developing COVID-19 therapeutics, all rising more […]
CureVac stock soars after $213.3M IPO
Shares of CureVac (NSDQ:CVAC) continue to rise after the company reportedly raised $213.3 million in its initial public offering on Friday. According to a report from MarketWatch, the Germany-based biotech outfit priced its IPO at $16 per share and sold more than 13.3 million shares to raise the $213.3 million. Currently, shares of CVAC are […]
Sanofi to acquire MS drug-development partner for $3.68B
Sanofi (NYSE:SNY) announced today that it agreed to acquire all outstanding shares of Principia Biopharma (NSDQ:PRNB) in a deal worth approximately $3.68 billion. The deal sets all outstanding shares of Principia at $100 per share, which will be acquired in cash. Sanofi and Principia both received unanimous approval from their respective boards of directors, according to […]
MedTech 100 roundup: Up-and-down week for industry
Medtech stocks highlighted the topsy-turvy nature of the market last week, but ultimately finished the seven days nearly unchanged. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — sat at 89.77 points at the end of last week (Aug. 14). Overall, medtech stocks saw a 0.13% increase from the […]
Accuray dips on mixed bag Q4
Accuray (NSDQ:ARAY) shares took a hit today on fourth-quarter results that were mixed compared to the consensus forecast. The Sunnyvale, Calif.-based radiotherapy device maker posted losses of -$823,000, or -1¢ per share, on sales of $94.98 million for the three months ended June 30, 2020, for a 41.2% bottom-line gain on a sales decline of -19.1%. […]
ReShape Lifesciences slides on Q2 losses
ReShape Lifesciences (OTC:RSLS) shares took a hit yesterday on second-quarter results that highlighted big losses. The San Clemente, Calif.-based obesity and metabolic disease treatment developer posted losses of -$3.6 million, or -52¢ per share, on sales of $1.7 million for the three months ended June 30, 2020, for a 77% bottom-line gain on a sales decline […]
Titan Medical reports improved financial position at end of Q2
Titan Medical (TSX:TMD;OTC:TITFX) faced a working capital deficit of $9.7 million more than a year ago. Fast forward 12 months, and the robotic surgery company has $21.7 million in working capital and has been able to resume product development. That seems to be the big takeaway from Titan Medical’s second-quarter earnings report, released yesterday. Titan executives […]
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 589
- Next Page »
